Plant free THCV

Gingko Bioworks and Cronos Group have announced the success of reaching their 3rd cultured cannabinoid milestone.

Ginkgo's platform has been used successfully by Cronos to achieve the productivity target for tetrahydrocannabivarin (THCV), a cannabinoid often associated with reducing appetite.

Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes

Δ9-Tetrahydrocannabivarin (THCV) is a cannabis-derived compound with unique properties that set it apart from the more common cannabinoids, such as Δ9-tetrahydrocannabinol (THC). The main advantage of THCV over THC is the lack of psychoactive ...

PubMed Central (PMC)Amos Abioye

The Gingko / Cronos partnership started in 2018 and has a stated aim to produce cultured cannabinoids at industrial scale.

Ginkgo has considerable experience designing microorganisms for the production of cultured products across pharmaceuticals, agriculture and more.

In August 2021, Ginkgo and Cronos achieved milestone #1 for cannabigerolic acid (CBGA).

In October 2021, Cronos launched the SPINACH FEELZ™ Chill Bliss 2:1 THC|CGB gummy and the SPINACH FEELZ™ Chill Bliss 7:1 THC|CBG vape in January 2022.